Corbus Pharmaceuticals secured FDA clearance for the Phase 3 TEMPO-1 study of CRB-701 in oropharyngeal cancer and announced leadership appointments to advance its clinical pipeline toward 2026 milestones.
Corbus Pharmaceuticals secured FDA clearance for the Phase 3 TEMPO-1 study of CRB-701 in oropharyngeal cancer and announced leadership appointments to advance its clinical pipeline toward 2026 milestones.